High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma

Bone Marrow Transplantation

Volumn 46, Issue 8, 2011, Pages 1156-1157

  Tuncer, H H ^a   Gregory, S A ^b   Fung, H C ^b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MELPHALAN; VINCRISTINE;

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMACYTOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 80051693304     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.251     Document Type: Letter

References (8)

1. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883. (Pubitemid 36532313)
2. Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Madrigal JA et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br J Haematol 2003; 123: 886-895. (Pubitemid 37533301)
3. Gerull S, Goerner M, Benner A, Hegenbart U, Klein U, Schaefer H et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36: 963-969. (Pubitemid 41741559)
4. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed multiple myeloma. N Engl J Med 2007; 356: 1110-1120. (Pubitemid 46425595)
5. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362.
6. van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 1135-1141. (Pubitemid 43871524)
7. Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656-663. (Pubitemid 38140101)
8. van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmye-loablative allogeneic stem cell transplantation. Blood 2006; 107: 3415-3416.